Skin rashes and stomatitis due to parenteral treatment of rheumatoid arthritis with sodium aurothiomalate.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 1533505.
- Also identified by PMC identifier 1004653.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In a prospective study of 45 patients with rheumatoid arthritis mucocutaneous symptoms and signs were evaluated before and during treatment with intramuscular sodium aurothiomalate (Myocrisin). The work, performed in close collaboration between dermatology and rheumatology departments, showed that there was no significant increase in mucocutaneous side effects in patients with pre-existing mucocutaneous disease. It is concluded that pre-existing dermatitis is not a contraindication for treatment with gold salts and that a previous mucocutaneous reaction to gold salts is not an absolute contraindication for a new trial of chrysotherapy.
Medical subject headings
- Arthritis, Rheumatoid
- Drug Eruptions
- Gold Sodium Thiomalate
- Stomatitis